In this context, it was recently suggested that treatment with a tolerogenic peptide resulted in reduced CD74 and CD44 expression [24] and may lead, via NF-κB-dependent signaling, to reduced CD69 expression and, consequently, to reduced anti-double-stranded DNA autoantibody production in a lupus mouse model. The gene discussed is CD69; the disease is systemic lupus erythematosus.